Evidence-informed pharmacology monograph, reviewed 10 November 2026. Educational content; drug administration and prescribing require current local labels, institutional protocols and individualized clinical assessment.
Overview and learning objectives
Labetalol is a mixed adrenergic antagonist that blocks vascular α1 receptors and cardiac/bronchial β1 and β2 receptors. It is used orally for selected chronic hypertension regimens and intravenously for selected severe hypertension in monitored settings. The clinical aims are to lower vascular resistance without excessive reflex tachycardia, recognize the contraindications to nonselective β-blockade, distinguish obstetric use from general hypertensive emergencies and understand why oral and IV treatment are not dose-interchangeable [1,2].
Receptor pharmacodynamics
Vascular α1 receptors activate Gq/PLC/IP3 and calcium-dependent contraction; antagonism decreases arteriolar resistance. β1 receptors in heart and kidney signal through Gs/cAMP to increase cardiac rate, contraction, conduction and renin secretion; β1 blockade reduces these effects. β2 receptors also use Gs and mediate bronchodilation, so β2 blockade can provoke clinically important bronchospasm. Labetalol’s α1 blockade tends to mitigate reflex tachycardia during vasodilation, but heart-rate suppression and hypotension are still possible [1].
Clinical indications and treatment selection
US labeling for IV labetalol specifies control of blood pressure in severe hypertension. Oral preparations treat hypertension. IV labetalol is also an established option in monitored severe hypertension during pregnancy and postpartum according to local obstetric guidance, but no agent suits every hypertensive emergency. Acute aortic syndromes, intracranial emergencies, pulmonary edema and other conditions have different recommended strategies. Labetalol is not a preferred treatment for decompensated heart failure, and its negative inotropic effect may aggravate overt cardiac failure [2,3].
Pharmacokinetics and route differences
Oral labetalol undergoes substantial hepatic first-pass metabolism; IV administration bypasses first pass and produces a more rapid, titratable effect. Hepatic glucuronidation is a major metabolic pathway. Metabolites are excreted in urine and bile, and dialysis does not efficiently remove circulating labetalol. Oral and IV doses, treatment intervals and titration should follow their distinct labels, blood-pressure goals and patient conditions [1,2].
Major contraindications
The current US injection label lists bronchial asthma, overt cardiac failure, heart block greater than first degree, cardiogenic shock and severe bradycardia among contraindications. This corrects the earlier article’s incorrect characterization of labetalol as broadly safe for heart-failure patients and in severe airway disease. Nonselective β blockade can also blunt the response to β2 rescue bronchodilators [2].
Adverse effects and interactions
Excessive BP reduction can cause dizziness, postural hypotension, syncope and organ hypoperfusion; bradycardia or AV block may occur. Rare severe hepatocellular injury, including fatalities, has been reported. Symptoms such as dark urine, jaundice, right upper quadrant discomfort and unexplained fatigue demand assessment. Combining with verapamil, diltiazem or other rate-slowing drugs can increase conduction risk. β blockade can mask tachycardia from hypoglycemia; caution is needed when abruptly withdrawing established therapy in coronary disease [2].
Monitoring and clinical example
During IV use, follow BP, pulse, ECG when appropriate, perfusion, airway status and response to gradual pressure reduction. In a pregnant patient with confirmed sustained severe BP elevation but no asthma, bradyarrhythmia or overt heart failure, IV labetalol may be considered in a supervised protocol; in a patient with active asthma and acute pulmonary edema, other tailored agents may be safer. The drug choice follows the emergency diagnosis, not an isolated BP number [2,3].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- DailyMed. Labetalol hydrochloride injection: prescribing information, indication, contraindications and hepatic injury warning. Updated October 2025. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dbf1e4c7-7c0c-4f2f-8cad-96bc6b800cfc
- American College of Obstetricians and Gynecologists. Emergent therapy for acute-onset, severe hypertension during pregnancy and postpartum. Committee Opinion No. 767. Obstet Gynecol. 2019;133:e174-e180. Available from: https://pubmed.ncbi.nlm.nih.gov/30575639/
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.